UK markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7400-0.0100 (-0.36%)
At close: 4:00PM EDT
2.7400 0.00 (0.00%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.7500
Open2.7600
Bid2.7300 x 4000
Ask2.8100 x 1100
Day's range2.7000 - 2.7900
52-week range1.8550 - 5.5500
Volume513,055
Avg. volume1,869,323
Market cap213.584M
Beta (5Y monthly)0.74
PE ratio (TTM)N/A
EPS (TTM)-1.3120
Earnings date03 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.50
  • Globe Newswire

    ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

    ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids- -Financing agreement with JGB Management to fund the planned launch of linzagolix as well as other development and operational expenses- - Amendment of Kissei exclusive license and supply agreement - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland, Oc

  • Globe Newswire

    ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Luigi Marro, as Chief Transformation Officer (CTO) and member of the company’s Executive Committee, effective October 1, 2021. Mr. Marro will lead the Company’s strategic Commercial Operational Readin

  • Zacks

    ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

    ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.